We are live on
!
Find out more
Lord, Abbett & Co Portfolio holdings
AUM
$30.6B
1-Year Est. Return
57.44%
This Fund
S&P 500
This Quarter
Est. Return
+6.45%
1 Year Est. Return
+57.44%
3 Year Est. Return
+215.76%
5 Year Est. Return
+368.6%
10 Year Est. Return
+2,376.62%
AUM
$30.8B
AUM Growth
+$741M
(+2.5%)
Cap. Flow
-$14.8B
Cap. Flow
% of AUM
-47.97%
Top 10 Holdings %
Top 10 Hldgs %
8.31%
Holding
851
New
152
Increased
227
Reduced
305
Closed
99
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dow Inc
DOW
|
+$92.3M |
| 2 |
Clorox
CLX
|
+$90.2M |
| 3 |
Universal Health Services
UHS
|
+$86.5M |
| 4 |
American International
AIG
|
+$81.4M |
| 5 |
Corteva
CTVA
|
+$74.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DHR.PRA
Danaher Corporation 4.75% Mandatory Convertible Preferred Stock, Series A
DHR.PRA
|
+$13.2B |
| 2 |
Bank of America
BAC
|
+$164M |
| 3 |
DuPont de Nemours
DD
|
+$120M |
| 4 |
Intuitive Surgical
ISRG
|
+$102M |
| 5 |
Johnson & Johnson
JNJ
|
+$93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.92% |
| 2 | Healthcare | 14.54% |
| 3 | Financials | 14.22% |
| 4 | Industrials | 11.55% |
| 5 | Consumer Discretionary | 10.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
Intellia Therapeutics
NTLA
$1.49B
| $4.64M | 0.02% |
283,286
-75,742
| -21% | -$1.19M |
|
602
AppFolio
APPF
$5.98B
| $4.57M | 0.01% |
44,684
-50,073
| -53% | -$4.73M |
|
|
ARNA
603
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $4.5M | 0.01% |
76,690
-35,039
| -31% | -$1.81M |
|
604
Belden
BDC
$4.12B
| $4.4M | 0.01% |
73,810
-155,952
| -68% | -$8.95M |
|
605
Bank of N.T. Butterfield & Son
NTB
$2.4B
| $4.33M | 0.01% |
+127,602
| New | +$4.71M |
|
606
Federated Hermes
FHI
$4.5B
| $4.28M | 0.01% |
+131,802
| New | +$4.16M |
|
607
Agilysys
AGYS
$2.91B
| $4.12M | 0.01% |
+191,699
| New | +$3.98M |
|
608
Seacoast Banking Corp of Florida
SBCF
$3.23B
| $4.11M | 0.01% |
161,422
-612,790
| -79% | -$15.9M |
|
609
Calix
CALX
$2.32B
| $4.07M | 0.01% |
619,690
+81,381
| +15% | +$549K |
|
610
CACI
CACI
$11B
| $4.05M | 0.01% |
+19,800
| New | +$3.92M |
|
611
FMC
FMC
$1.39B
| $4.04M | 0.01% |
48,663
-245,671
| -83% | -$19.3M |
|
612
Tetra Tech
TTEK
$8.28B
| $3.99M | 0.01% |
+254,250
| New | +$3.43M |
|
613
Prosperity Bancshares
PB
$8.69B
| $3.91M | 0.01% |
+59,200
| New | +$4.1M |
|
614
DXC Technology
DXC
$1.68B
| $3.88M | 0.01% |
70,259
-32,842
| -32% | -$1.9M |
|
|
TGI
615
DELISTED
Triumph Group
TGI
| $3.85M | 0.01% |
+168,303
| New | +$3.62M |
|
616
National Beverage
FIZZ
$2.93B
| $3.62M | 0.01% |
+162,000
| New | +$4.17M |
|
|
BMTC
617
DELISTED
Bryn Mawr Bank Corp
BMTC
| $3.61M | 0.01% |
96,761
-14,079
| -13% | -$527K |
|
618
Edwards Lifesciences
EW
$47.8B
| $3.52M | 0.01% |
57,243
-470,448
| -89% | -$28.4M |
|
619
Chewy
CHWY
$8.93B
| $3.46M | 0.01% |
+98,839
| New | +$3.34M |
|
620
Ross Stores
ROST
$78.1B
| $3.44M | 0.01% |
+34,667
| New | +$3.38M |
|
621
Exponent
EXPO
$3.04B
| $3.37M | 0.01% |
57,491
+9,491
| +20% | +$540K |
|
622
FB Financial Corp
FBK
$2.94B
| $3.28M | 0.01% |
89,622
-50,337
| -36% | -$1.78M |
|
623
Wingstop
WING
$3.74B
| $3.2M | 0.01% |
33,805
-8,195
| -20% | -$668K |
|
624
Monro
MNRO
$529M
| $2.95M | 0.01% |
34,592
-95,079
| -73% | -$7.93M |
|
625
D.R. Horton
DHI
$41.3B
| $2.89M | 0.01% |
+67,000
| New | +$2.97M |
|
Similar funds
Lord, Abbett & Co's Q2 2019 Portfolio in Review
As of Q2 2019, Lord, Abbett & Co held 851 positions worth $30.8B, up 2.5% from $30B the previous quarter. Its ten largest holdings account for 8.3% of the portfolio.
Lord, Abbett & Co withdrew a net $14.8B in Q2 2019, closing 99 positions and reducing 305 holdings. Its most notable exit was DuPont de Nemours, an estimated $120M position sold in full.
By sector, the portfolio is most concentrated in Technology at 16% of assets, down from 16% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Lord, Abbett & Co opened a new position in Dow Inc worth $86.2M.
- Lord, Abbett & Co's largest Q2 2019 buy was Dow Inc: 1,747,600 shares worth $86.2M.
- Lord, Abbett & Co added most to Clorox in Q2 2019, an estimated $90.2M increase.
- Lord, Abbett & Co's biggest Q2 2019 reduction was Danaher Corporation 4.75% Mandatory Convertible Preferred Stock, Series A, cutting an estimated $13.2B.
- Lord, Abbett & Co fully exited DuPont de Nemours in Q2 2019, selling an estimated $120M.
- Lord, Abbett & Co's ten largest holdings make up 8.3% of its $30.8B portfolio in Q2 2019.
- Lord, Abbett & Co opened 152 new positions and closed 99 in Q2 2019.
- Lord, Abbett & Co's portfolio value rose 2.5% quarter-over-quarter to $30.8B.
Based on Lord, Abbett & Co's 13F filing for Q2 2019, filed 14 Aug 2019.